tiprankstipranks
Abbott Laboratories (MX:ABT)
:ABT
Mexico Market
ABT
Abbott Laboratories
RESEARCH TOOLSreports

Abbott Laboratories (ABT) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ABT Analyst Ratings

Strong Buy
15Ratings
Strong Buy
15 Buy
0 Hold
0 Sell
Based on 15 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABT Stock 12 Month Forecast

Average Price Target

$2,109.96
▲(7.10% Upside)
Based on 15 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $2,109.96 with a high forecast of $2,290.97 and a low forecast of $1,900.66. The average price target represents a 7.10% change from the last price of $1,970.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1491":"$1,491","2378":"$2,378","1712.75":"$1,712.8","1934.5":"$1,934.5","2156.25":"$2,156.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2290.97018385,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.29K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2109.955255743333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1900.6567451199999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.90K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1491,1712.75,1934.5,2156.25,2378],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1850,1883.920783373077,1917.8415667461538,1951.7623501192309,1985.6831334923077,2019.6039168653847,2053.5247002384617,2087.4454836115383,2121.3662669846153,2155.2870503576924,2189.2078337307694,2223.128617103846,2257.049400476923,{"y":2290.97018385,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1850,1869.9965581341025,1889.993116268205,1909.9896744023076,1929.9862325364102,1949.9827906705127,1969.9793488046153,1989.9759069387178,2009.9724650728203,2029.9690232069229,2049.9655813410254,2069.962139475128,2089.9586976092305,{"y":2109.955255743333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1850,1853.8966727015384,1857.793345403077,1861.6900181046153,1865.586690806154,1869.4833635076923,1873.3800362092306,1877.2767089107692,1881.1733816123076,1885.070054313846,1888.9667270153845,1892.863399716923,1896.7600724184615,{"y":1900.6567451199999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2377.276,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2330.581,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2258.181,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2321.708,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2228.824,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1884.98,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1953.736,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1816.58,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1573.799,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1492.349,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1581.246,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1824,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1850,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$2,291Average Price Target$2,110Lowest Price Target$1,901
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:ABT
Joanne Wuensch
Citi
Citi
$2,121.27
Buy
7.68%
Upside
Reiterated
09/10/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO), EyePoint Pharmaceuticals (NASDAQ: EYPT) and Abbott Laboratories (NYSE: ABT)
Wells Fargo Analyst forecast on MX:ABT
Larry Biegelsen
Wells Fargo
Wells Fargo
$1,900.66
Buy
-3.52%
Downside
Reiterated
09/08/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Pharvaris (NASDAQ: PHVS) and Zimmer Biomet Holdings (NYSE: ZBH)
J.P. Morgan Analyst forecast on MX:ABT
Robbie Marcus
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (NASDAQ: PMVP), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Abbott Laboratories (NYSE: ABT)
TD Cowen Analyst forecast on MX:ABT
Josh Jennings
TD Cowen
TD Cowen
$2,290.97
Buy
16.29%
Upside
Reiterated
08/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (NYSE: ABT), PTC Therapeutics (NASDAQ: PTCT) and Ansell (Other OTC: ANSLF)
Piper Sandler Analyst forecast on MX:ABT
Adam Maeder
Piper Sandler
Piper Sandler
$2,002.48
Buy
1.65%
Upside
Reiterated
08/26/26
Piper Sandler Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Jefferies Analyst forecast on MX:ABT
Matthew Taylor
Jefferies
Jefferies
$2,290.97
Buy
16.29%
Upside
Reiterated
08/21/26
Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)
William Blair Analyst forecast on MX:ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/21/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Doximity (NYSE: DOCS)
Bank of America Securities Analyst forecast on MX:ABT
Travis Steed
Bank of America Securities
Bank of America Securities
$1,951.57
Buy
-0.94%
Downside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Savara (NASDAQ: SVRA), AptarGroup (NYSE: ATR) and Abbott Laboratories (NYSE: ABT)
BTIG Analyst forecast on MX:ABT
Marie Thibault
BTIG
BTIG
$2,274
Buy
15.43%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Alvotech (NASDAQ: ALVO) and Abbott Laboratories (NYSE: ABT)
Wolfe Research Analyst forecast on MX:ABT
Michael Polark
Wolfe Research
Wolfe Research
$2,206.12
Buy
11.99%
Upside
Upgraded
08/13/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Abbott Laboratories (ABT)
UBS Analyst forecast on MX:ABT
Patrick Wood
UBS
UBS
$2,290.97→$2,121.27
Buy
7.68%
Upside
Assigned
07/28/26
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
Raymond James Analyst forecast on MX:ABT
Jayson Bedford
Raymond James
Raymond James
―
Buy
―
Reiterated
07/17/26
Abbott Laboratories (ABT) Gets a Buy from Raymond James
RBC Capital Analyst forecast on MX:ABT
Shagun Singh Chadha
RBC Capital
RBC Capital
$2,206.12
Buy
11.99%
Upside
Reiterated
07/16/26
RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Evercore ISI Analyst forecast on MX:ABT
Vijay Kumar
Evercore ISI
Evercore ISI
$2,036.42→$1,900.66
Buy
-3.52%
Downside
Reiterated
07/06/26
Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI
Robert W. Baird Analyst forecast on MX:ABT
David Rescott
Robert W. Baird
Robert W. Baird
$2,053.39
Buy
4.23%
Upside
Initiated
06/30/26
Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on MX:ABT
Joanne Wuensch
Citi
Citi
$2,121.27
Buy
7.68%
Upside
Reiterated
09/10/26
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (NASDAQ: BBIO), EyePoint Pharmaceuticals (NASDAQ: EYPT) and Abbott Laboratories (NYSE: ABT)
Wells Fargo Analyst forecast on MX:ABT
Larry Biegelsen
Wells Fargo
Wells Fargo
$1,900.66
Buy
-3.52%
Downside
Reiterated
09/08/26
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (NYSE: ABT), Pharvaris (NASDAQ: PHVS) and Zimmer Biomet Holdings (NYSE: ZBH)
J.P. Morgan Analyst forecast on MX:ABT
Robbie Marcus
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
09/01/26
Analysts Offer Insights on Healthcare Companies: PMV Pharmaceuticals (NASDAQ: PMVP), Arrowhead Pharmaceuticals (NASDAQ: ARWR) and Abbott Laboratories (NYSE: ABT)
TD Cowen Analyst forecast on MX:ABT
Josh Jennings
TD Cowen
TD Cowen
$2,290.97
Buy
16.29%
Upside
Reiterated
08/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Abbott Laboratories (NYSE: ABT), PTC Therapeutics (NASDAQ: PTCT) and Ansell (Other OTC: ANSLF)
Piper Sandler Analyst forecast on MX:ABT
Adam Maeder
Piper Sandler
Piper Sandler
$2,002.48
Buy
1.65%
Upside
Reiterated
08/26/26
Piper Sandler Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Jefferies Analyst forecast on MX:ABT
Matthew Taylor
Jefferies
Jefferies
$2,290.97
Buy
16.29%
Upside
Reiterated
08/21/26
Jefferies Sticks to Their Buy Rating for Abbott Laboratories (ABT)
William Blair Analyst forecast on MX:ABT
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
08/21/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abbott Laboratories (NYSE: ABT) and Doximity (NYSE: DOCS)
Bank of America Securities Analyst forecast on MX:ABT
Travis Steed
Bank of America Securities
Bank of America Securities
$1,951.57
Buy
-0.94%
Downside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Savara (NASDAQ: SVRA), AptarGroup (NYSE: ATR) and Abbott Laboratories (NYSE: ABT)
BTIG Analyst forecast on MX:ABT
Marie Thibault
BTIG
BTIG
$2,274
Buy
15.43%
Upside
Reiterated
08/20/26
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (NASDAQ: CORT), Alvotech (NASDAQ: ALVO) and Abbott Laboratories (NYSE: ABT)
Wolfe Research Analyst forecast on MX:ABT
Michael Polark
Wolfe Research
Wolfe Research
$2,206.12
Buy
11.99%
Upside
Upgraded
08/13/26
Analysts' Top Healthcare Picks: Liquidia Technologies (LQDA), Abbott Laboratories (ABT)
UBS Analyst forecast on MX:ABT
Patrick Wood
UBS
UBS
$2,290.97→$2,121.27
Buy
7.68%
Upside
Assigned
07/28/26
UBS Issues a Buy Rating on Abbott Laboratories (ABT)
Raymond James Analyst forecast on MX:ABT
Jayson Bedford
Raymond James
Raymond James
―
Buy
―
Reiterated
07/17/26
Abbott Laboratories (ABT) Gets a Buy from Raymond James
RBC Capital Analyst forecast on MX:ABT
Shagun Singh Chadha
RBC Capital
RBC Capital
$2,206.12
Buy
11.99%
Upside
Reiterated
07/16/26
RBC Capital Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Evercore ISI Analyst forecast on MX:ABT
Vijay Kumar
Evercore ISI
Evercore ISI
$2,036.42→$1,900.66
Buy
-3.52%
Downside
Reiterated
07/06/26
Abbott price target lowered to $112 from $120 at Evercore ISIAbbott price target lowered to $112 from $120 at Evercore ISI
Robert W. Baird Analyst forecast on MX:ABT
David Rescott
Robert W. Baird
Robert W. Baird
$2,053.39
Buy
4.23%
Upside
Initiated
06/30/26
Abbott initiated with an Outperform at BairdAbbott initiated with an Outperform at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
STOKStoke Therapeutics
AXGNAxoGen
JAZZJazz Pharmaceuticals
PTGXProtagonist Therapeutics
CABACabaletta Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abbott Laboratories

3 Months
Matthew TaylorJefferies
Success Rate
17/23 ratings generated profit
74%
Average Return
+2.63%
Copying Matthew Taylor's trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +2.63% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
35/44 ratings generated profit
80%
Average Return
+15.70%
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 79.55% of your transactions generating a profit, with an average return of +15.70% per trade.
2 Years
Matthew TaylorJefferies
Success Rate
16/23 ratings generated profit
70%
Average Return
+26.26%
Copying Matthew Taylor's trades and holding each position for 2 Years would result in 69.57% of your transactions generating a profit, with an average return of +26.26% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABT Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
33
38
33
42
34
Hold
6
5
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
43
33
42
34
In the current month, ABT has received 34 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ABT average Analyst price target in the past 3 months is 2,109.96.
Each month's total comprises the sum of three months' worth of ratings.

ABT Financial Forecast

ABT Earnings Forecast

Next quarter’s earnings estimate for ABT is $24.04 with a range of $23.73 to $24.39. The previous quarter’s EPS was $22.19. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABT is $24.04 with a range of $23.73 to $24.39. The previous quarter’s EPS was $22.19. ABT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Sales Forecast

Next quarter’s sales forecast for ABT is $220.07B with a range of $218.50B to $222.88B. The previous quarter’s sales results were $213.33B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.
Next quarter’s sales forecast for ABT is $220.07B with a range of $218.50B to $222.88B. The previous quarter’s sales results were $213.33B. ABT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ABT has Performed in-line its overall industry.

ABT Stock Forecast FAQ

What is MX:ABT’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is 2,109.96.
    What is MX:ABT’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 7.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 15 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is 2,109.96. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $2,290.97 ,and the lowest forecast is $1,900.66. The average share price target represents 7.10% Increase from the current price of $1,970.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of MX:ABT, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.